Immunologic aspects of osteoporosis

Developmental and Comparative Immunology

Volumn 21, Issue 6, 1997, Pages 487-499

  Ershler, William B ^a,b,c   Harman, S Mitchell ^a   Keller, Evan T ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Aging; Estrogen; Interleukin 6; Osteoclast; Osteoporosis

Indexed keywords

ANDROGEN; ESTROGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SOMATOMEDIN C;

AGING; BONE REMODELING; HUMAN; IMMUNE SYSTEM; MENOPAUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0031446261     PISSN: 0145305X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-305X(97)00029-3     Document Type: Article

References (127)

1. Manolagas, S. C.; Jilka, R. L. Bone marrow, cytokines, and bone remodelling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332(5):305-311; 1995.
2. Horowitz, M. C. Cytokines and estrogen in bone: Anti-osteoporotic effects. Science 260:626-627; 1993.
3. Cummings, S. R.; Kelsey, J. L.; Nevitt, M. C.; O'Dowd, K. J. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol. Rev. 7:178-208; 1985.
4. Riggs, B. L.; Melton, L. Jr. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5):505S-511S; 1995.
5. Christiansen, C. Skeletal osteoporosis. J. Bone Miner. Res. 8(2):S475-480; 1993.
6. Orwoll, E. S.; Klein, R. F. Osteoporosis in men. Endocrine Rev. 16:87-116; 1995.
7. Kelepouris, N.; Harper, K. D.; Gannon, F.; Kaplan, F. S.; Haddad, J. G. Severe osteoporosis in men. Ann. Int. Med. 123:452-460; 1995.
8. Bendavid, E. J.; Shan, J.; Barrett-Conor, E. Factors associated with bone mineral density in middle-aged men. J. Bone Miner. Res. 11:1185-1190; 1996.
9. Gunby, M. C.; Morley, J. E. Epidemiology of bone loss with aging. Clin. Geriatr. Med. 10:557-574; 1994.
10. Chrischilles, E. A.; Butler, D.; Davis, C. S.; Wallace, R. B. A. I. M. A model of lifetime osteoporosis impact. Arch. Int. Med. 151:2026-2032; 1991.
11. Melton, L. Jr. Epidemiology of hip fractures: implications of the exponential increase with age. Bone 18(3):121S-125S; 1996.
12. Kannus, P.; Parkkari, J.; Sievanen, H.; Heinonen, A.; Vuori, I.; Jarvinen, M. Epidemiology of hip fractures. Bone 18(1):57S-63S; 1996.
13. White, B. L.; Fisher, W. D.; Laurin, C. A. Rate of mortality for elderly patients after fractures of the hip in the 1980's. J. Bone Joint Surgery 69A:1335-1340; 1987.
14. Fitzgerald, J. F.; Moore, P. S.; Dittus, R. S. The care of elderly patients with hip fractures. Changes since implementation of the prospective payment system. N. Engl. J. Med. 319:1392-1397; 1988.
15. Seeman, E. The dilemma of osteoporosis in men. Am. J. Med. 98(2A):76S-88S; 1995.
16. Jackson, H. A.; Kleerkoper, M. Osteoporosis in men: Diagnosis, pathophysiology, and prevention. Medicine 69:137-152; 1990.
17. Nguyen, T. V.; Eisman, J. A.; Kelly, P. J.; Sambrook, P. N. Risk factors for osteoporotic fractures in elderly men. Am. J. Epidemiol. 144:255-263; 1996.
18. Jones, G., White, C., Nguyen, T., Sambrook, P. N., Kelly, P. J. and Eisman, J. A. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos. Int. 6:233-239; 1996.
19. Resch, A.; Schneider, B.; Bernecker, P. Risk of vertebral fractures in men: relationship to mineral density of the vertebral body. Am. J. Roentgenol. 164(6):1447-1450; 1995.
20. Krall, E. A.; Dawson-Hughes, B.; Hirst, K.; Gallagher, J. C.; Sherman, S. S.; Dalsky, G. Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women. J. Gerontol. 52A:M61-M67; 1997.
21. Edwards, B. J.; Perry III, H. M. Age-related osteoporosis. Clin. Geriatr. Med. 10:575-588; 1994.
22. Parfitt, A. M.; Villanueva, A. R.; Foldes, J.; Sudhaker, R. D. Relations between histoloic indices of bone formation: Implications for the pathogenesis of spinal osteoporosis. J. Bone Miner. Res. 10:466-473; 1995.
23. Lips, P.; Courpron, P.; Meunier, P. Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age. Calcif. Tissue Int. 26:13-17; 1978.
24. Recker, R. R.; Kimmel, D. B.; Parfitt, A. M.; Davies, K. M.; Keshwarz, N.; Hinders, S. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J. Bone Miner. Res. 3:133-144; 1988.
25. Okamoto, Y.; Takahashi, K.; Toriyama, K.; Takeda, N.; Kitagawa, K.; Hosokawa, M.; Takeda, T. Femoral peak bone mass and osteoclast number in an animal model of age-related spontaneous osteopenia. Anat. Record 242:21-28; 1995.
26. Jilka, R. L.; Weinstein, R. S.; Takahashi, K.; Parfitt, A. M.; Manolagas, S. C. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Invest. 97(7):1732-1740; 1996.
27. Kahn, A.; Gibbons, R.; Perkins, S.; Gazit, D. Age-related bone loss. Clin. Orth. Rel. Res. 313:69-75; 1995.
28. Matayoshi, A., Brown, C. and Pacifici, R. Generation of human osteoclasts from peripheral blood hematopoietic precursors cells in absence of stromal cells: Effects of estrogen and aging. J. Bone Miner. Res. 1996, 11(1), S282 (Abs M401).
29. Suda, T.; Udagawa, N.; Nakamura, I.; Miyaura, C.; Takahashi, N. Modulation of osteoclast differentiation by local factors. Bone 17(2):87S-91S; 1995.
30. Felix, R.; Genolet, C. L.; Lowik, C.; Cecchini, M. G.; Hofstetter, W. Cytokine production by calvariae of osteopetrotic mice. Bone 17:5-9; 1995.
31. Morohashi, T.; Corboz, V. A.; Fleisch, H.; Cecchinin, M. G.; Felix, R. Macrophage colony-stimulating factor restores bone resorption in op/op bone in vitro in conjunction with parathyroid hrmone or 1,25-dihydroxyvitamin D3. J. Bone Miner. Res. 9:401-407; 1994.
32. Philippart, C.; Tzehoval, E.; Moricard, Y.; Bringuier, A. F.; Seebold, C.; Lemoine, F. M.; Arys, A.; Dourov, N.; Labat, M. L. Immune cell defects affect bone remodelling in osteoporotic op/op mice. Bone Miner. 23:317-332; 1993.
33. Blackman, M. R.; Weintraub, B. D.; Rosen, S. W.; Harman, S. M. Comparison of the effects of lung cancer, benign lung disease, and normal aging on pituitary-gonadal function in men. J. Clin. Endocrinol. Metab. 66:88-95; 1988.
34. Harman, S. M.; Tsitouras, P. D. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone and Leydig cell response to human chorionic gonadotropin. J. Clin. Endocrinol. Metab. 51:35-41; 1980.
35. Nieschlag, E.; Lammer, U.; Freischem, C. W.; Langer, K.; Wickings, E. J. Reproductive function in young fathers and grandfathers. J. Clin. Endocrinol. Metab. 51:675-681; 1982.
36. Vermeulen, A. Clinical review 24: Androgens in the aging male. J. Clin. Endocrinol. Metab. 73:221-224; 1991.
37. Tenover, J. S.; Matsumoto, A. M.; Plymate, S. R.; Bremner, W. J. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: Response to clomiphene citrate. J. Clin. Endocrinol. Metab. 65:1118-1126; 1987.
38. Nankin, H. R.; Calkins, J. H. Decreased bioavailable testosterone in aging normal and impotent men. J. Clin. Endocrinol. Metab. 63:1418-1420; 1986.
39. Nahoul, K.; Roger, M. Age related decline of plasma bioavailable testosterone in adult men. J. Steroid Biochem. Molec. Biol. 35:293-299; 1990.
40. Corpas, E.; Harman, S. M.; Blackman, M. R. Human growth hormone and human aging. Endocrine Reviews 14:20-39; 1993.
41. Finkelstein, J.; Roffwarg, H.; Boyar, P.; Kream, J.; Hellman, L. Age-related changes in the twenty-four hour spontaneous secretion of growth hormone in normal individuals. J. Clin. Endocrinol. Metab. 35:665-670; 1972.
42. Zadik, Z.; Chalew, S. A.; McCarter, R. J.; Meistas, M.; Kowarski, A. A. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J. Clin. Endocrinol. Metab. 60:513-516; 1985.
43. Ho, K. Y.; Evans, W. S.; Blizzard, R. M. Effects of sex and age on 24-hour profile of growth hormone secretion in men: Importance of endogenous estradiol concentrations. J. Clin. Endocrinol. Metab. 64:51-58; 1987.
44. Vermeulen, A. Nyctohemoral growth hormone profiles in young and aged men: Correlations with somatomedin-C levels. J. Clin. Endocrinol. Metab. 64:884-888; 1987.
45. Corpas, E.; Harman, S. M.; Piñeyro, M. A.; Roberson, R.; Blackman, M. R. GHRH 1-29 twice daily reverses the decreased GH and IGF-I levels in old men. J. Clin. Endocrinol. Metab. 75:530-535; 1992.
46. Lang, I.; Schernthaner, G.; Pietschmann, P.; Kurz, R.; Stephenson, J. M.; Templ, M. Effects of sex and age on growth hormone response to growth hormone releasing hormone in healthy individuals. J. Clin. Endocrinol. Metab. 65:535-540; 1987.
47. Bellantoni, M. F.; Harman, S. M.; Cho, D.; Blackman, M. R. Effects of progestin-opposed transdermal estrogen administration on GH and IGF-I in postmenopausal women of different ages. J. Clin. Endocrinol. Metab. 72:172-178; 1991.
48. Shibasaki, T.; Shizume, K.; Nakahara, M. Age-related changes in plasma growth hormone response to growth hormone-releasing factor in man. J. Clin. Endocrinol. Metab. 58:212-214; 1984.
49. Iovino, M.; Monteleone, P.; Steardo, L. Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH releasing hormone testing in normal aging. J. Clin. Endocrinol. Metab. 69:910-913; 1989.
50. Coiro, V.; Volpi, R.; Cavazzini, U. Restoration of normal growth hormone responsiveness to GHRH in normal aged men by infusion of low amounts of theophylline. J. Gerontol. 46:M155-158; 1991.
51. Corpas, E.; Harman, S. M.; Piñeyro, M. A.; Roberson, R.; Blackman, M. R. Continuous subcutaneous infusions of GHRH 1-44 for 14 days increase GH and IGF-I levels in old men. J. Clin. Endocrinol. Metab. 76:134-138; 1993.
52. Pavlov, E. P.; Harman, S. M.; Merriam, G. R.; Gelato, M. C.; Blackman, M. R. Responses of growth hormone and somatomedin-C to GH-releasing hormone in healthy aging men. J. Clin. Endocrinol. Metab. 62:595-600; 1986.
53. Seeman, E.; Melton, I. E. J. Risk factors for spinal osteoporosis in men. Am. J. Med. 75:977-983; 1983.
54. Jackson, J. A.; Kleerekoper, M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine 69:137-152; 1990.
55. Francis, R. M.; Peachick, M.; Marshall, D. H.; Horsman, A.; Aaron, J. E. Spinal osteoporosis in men. Bone Miner. 5:347-357; 1989.
56. Stanley, H. L.; Schmitt, B. P.; Poses, R. M.; Deiss, W. P. Does hypogonadism contribute to the occurrence of minimal trauma hip fracture in elderly men? J. Am. Geriatr. Soc. 39:766-771; 1991.
57. Nachtigall, L. E.; Nachtigall, R. H.; Nachtigall, R. D.; Beckman, E. M. Estrogen replacement therapy I: A 10-year study in the relationship to osteoporosis. Obstetr. Gynecol. 53:277-281; 1979.
58. Prince, R. L., Smith, M., Dick, I. M., et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N. Engl. J. Med. 325:1189-1195; 1991.
59. Quigley, M. E. T.; Martin, P. L.; Burnier, A. M.; Brooks, P. Estrogen therapy arrests bone loss in elderly women. Am. J. Obstetr. Gynecol. 156:1516-1523; 1987.
60. Ettinger, B.; Genant, H. K.; Cann, C. E. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann. Intern. Med. 102:319-324; 1985.
61. Weiss, N. S.; Ure, C. L.; Ballard, J. H.; Williams, A. R.; Daling, J. R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N. Engl. J. Med. 303:1195-1198; 1980.
62. Cauley, J. A.; Seeley, D. G.; Ensrud, K.; Ettinger, B.; Black, D.; Cummings, S. R. Estrogen replacement therapy and fractures in older women. Ann. Intern. Med. 122:9-16; 1995.
63. Finkelstein, J. S.; Klibanski, A.; Neer, R. M. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 69:776-783; 1989.
64. Diamond, T.; Stiel, D.; Posen, S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J. Bone Miner. Res. 6:39-43; 1991.
65. Isaia, G.; Mussetta, M.; Pecchio, F.; Sciolla, A.; di Stefano, M.; Molinatti, G. M. Effect of testosterone on bone in hypogonadal males. Maturitas 15:47-51; 1992.
66. Devogelaer, J. P.; DeCooman, S.; Nagant de Deuxchaisnes, C. Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas 15:17-23; 1992.
67. Bertelloni, D.; Baroncelli, G. I.; Battini, R.; Perii, G.; Saggese, G. Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. J. Bone Miner. Res. 10:1488-1495; 1995.
68. Wang, C.; Eyre, D. R.; Clark, R. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men-a clinical research center study. J. Clin. Endocrinol. Metab. 81:3654-3662; 1996.
69. Jackson, J. A.; Kleerekoper, M.; Parfitt, A. M.; Rao, D. S.; Villaneuva, A. R.; Frame, B. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J. Clin. Endocrinol. Metab. 65:53-58; 1987.
70. Rosen, T.; Hansson, T.; Granhed, H.; Szucs, J.; Bengtsson, B. A. A. E. C. S. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. (Kbh) 129(3):201-206; 1993.
71. O'Halloran, D. J.; Tsatsoulis, A.; Whitehouse, R. W.; Holmes, S. J.; Adams, J. E.; Shalet, S. M. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J. Clin. Endocrinol. Metab. 76:1344-1348; 1993.
72. Johannson, G.; Rosen, T.; Bosaeus, I.; Sjostrom, L.; Bengtsson, B.-A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 81:2865-2873; 1996.
73. Rudman, D.; Feller, A. G.; Nagraj, H. S. Effect of human growth hormone in men over 60 years old. N. Engl. J. Med. 323:1-6; 1990.
74. Holloway, L.; Butterfield, G.; Hintz, R.; Geusundheit, N.; Marcus, R. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J. Clin. Endocrinol. Metab. 79:470-479; 1994.
75. Murasko, D. M.; Goonewardene, I. M. T cell function in aging: Mechanisms of decline. Ann. Rev. Gerontol. Geriatr. 10:71-96; 1990.
76. Chopra, R. K.; Powers, D. C.; Kendig, N. E.; Adler, W. H.; Nagel, J. E. Interleukin 2, interleukin 2 receptor and interferon g synthesis and mRNA expression in phorbol myrisate acetate and calcium ionophore A23187 stimulated T cells from elderly humans. Clin. Immunol. Immunopathol. 53:297-308; 1989.
77. Tang, B.; Matsuda, T.; Akira, S.; Nagata, N.; Ikehara, S.; Hirano, T.; Kishimoto, T. Age-associated increase in interleukin 6 in MRL/1pr mice. Int. Immunol. 3:273-278; 1991.
78. Suzuki, H.; Yasukawa, K.; Saito, T.; Narazaki, M.; Hasegawa, A.; Taga, T.; Kishimoto, T. Serum soluble interleukin-6 receptor in MRL/1pr mice is elevated with age and mediates the interleukin-6 signal. Eur. J. Immunol. 23:1078-1082; 1993.
79. Effros, R. B.; Svoboda, K.; Walford, R. L. Influence of age and caloric restriction on macrophage IL-6 and TNF production. Lymphokine Cytokine Res. 10(5):347-351; 1991.
80. Zhou, D.; Chrest, F. J.; Adler, W.; Munster, A.; Winchurch, R. A. Increased production of TGF-beta and IL-6 by aged spleen cells. Immunology Letters 36:7-11; 1993.
81. Foster, K. D.; Conn, C. A.; Kluger, M. J. Fever, tumor necrosis factor, and interlukin-6 in young, mature, and aged Fischer 344 rats. Am. J. Physiol. 262:R211-R215; 1992.
82. Wei, J.; Xu, H.; Davies, J. L.; Hemmings, G. P. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sciences 51:1953-1956; 1992.
83. Goya, R. G.; Gagnerault, M. C.; De Moraes, M. C.; Savino, W.; Dardenne, M. In vivo effects of growth hormone on thymus function in aging mice. Brain Behav. Immunol. 6:341-354; 1992.
84. Daynes, R. A.; Araneo, B. A.; Ershler, W. B.; Maloney, C.; Li, G. Z.; Ryu, S. Y. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J. Immunol. 150:5219-5230; 1993.
85. Ershler, W. B.; Sun, W. H.; Binkley, N.; Gravenstein, S.; Volk, M. J.; Kamoske, G.; Klopp, R. G.; Roecker, E. B.; Daynes, R. A.; Weindruch, R. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 12(4):225-230; 1993.
86. Sindermann, J.; Kruse, A.; Frercks, H. J.; Schutz, R. M.; Kirchner, H. Investigations of the lymphokine system in elderly individuals. Mech. Ageing Dev. 70:149-159; 1993.
87. McKane, R.; Khosla, S.; Peterson, J.; Egan, K.; Riggs, B. L. Effect of age and menopause on serum interleukin-6 levels in women. J. Bone Miner. Res. 8(1):S157; 1993.
88. Fagiolo, U.; Cossarizza, A.; Scala, E.; Fanales-Belasio, E.; Ortolani, C.; Cozzi, E.; Monti, D.; Franceschi, C.; Paganelli, R. Increased cytokine production in mononuclear cells of healthy elderly people. Eur. J. Immunol. 23(9):2375-2378; 1993.
89. Liao, Z.; Caucino, J. A.; Schnipper, S. M.; Stanley, E. R.; Small, C. B.; Rosenstreich, D. L. Increased urinary cytokines in the elderly. Aging Immunol. Infect. Dis. 4:139-153; 1993.
90. Kania, D. M.; Binkley, N.; Checovich, M.; Havighurst, T.; Schilling, M.; Ershler, W. B. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J. Am. Geriatr. Soc. 43:236-239; 1995.
91. Bellido, T.; Girasole, G.; Passeri, G.; Yu, X. P.; Jilka, R. L.; Boder, G.; Williams, D. C.; Boswell, S.; Notides, A.; Manolagas, S. C. Demonstration of estrogen receptors by western blot analysis in bone marrow stromal cells and osteoblasts: Correlation with interleukin-6 regulation by estrogens and antiestrogens. J. Bone Miner. Res. 6(1):S88; 1991.
92. Girasole, G.; Jilka, R. L.; Passeri, G.; Boswell, G.; Boder, G.; Williams, D. C.; Manolagas, S. C. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:883-891; 1992.
93. Girasole, G.; Passeri, G.; Knutson, S.; Manolagas, S. C.; Jilka, R. L. Upregulation of osteoclastogenic potential of the marrow is induced by orchiectomy and is reversed by testosterone replacement in the mouse. J. Bone Miner. Res. 7(1):596; 1992.
94. Passeri, G.; Girasole, G.; Markus, T.; Abrams, J. S.; Manolagas, S. C.; Jilka, R. L. 17β estradiol regulates IL-6 production and osteoclast development in murine calvaria cell cultures. J. Bone Miner. Res. 6(1):S263; 1991.
95. Jilka, R. L.; Hangoc, G.; Girasole, G.; Passeri, G.; Williams, D. C.; Abrams, J. S.; Boyce, B.; Broxmeyer, H.; Manolagas, S. C. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88-91; 1992.
96. Keller, E. T.; Chang, C.; Ershler, W. B. Inhibition of NFκB activity through maintenance of IkBa levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J. Biol. Chem. 271:26267-26275; 1996.
97. Kishimoto, T.; Akira, S.; Taga, T. IL-6 receptor and mechanism of signal transduction. Int. J. Immunopharmac. 14:431-438; 1992.
98. Taga, T.; Kishimoto, T. Cytokine receptors and signal transduction. FASEB J. 7:3387-3396; 1993.
99. Novick, D.; Englmann, H.; Wallach, D.; Rubinstein, M. Soluble cytokine receptors are present in normal human urine. J. Expl. Med. 170:1409-1414; 1989.
100. Lorenzo, J. A. The role of cytokines in the regulation of local bone resorption. Crit. Rev. Immunol. 11:195-213; 1991.
101. Bellido, T.; Girasole, G.; Passeri, G.; Jilka, R. L.; Manolagas, S. C. Sex steroids regulate the expression of the gp130 transduction pathway by bone marrow and bone cells. Bone Miner. 25(S1):S39; 1994.
102. Fang, M. A.; Hahn, T. J. Effects of interleukin-6 on cellular function in UMR-106-01 osteoblast-like cells. J. Bone Miner. Res. 6:133-139; 1991.
103. Taguchi, Y.; Yamate, T.; Mocharia, H.; Lin, S. C.; Verino, A.; DeTogni, P.; Abe, E.; Manolagas, S. C. Interleukin-6 induces osteoblast differentiation in uncommitted embryonic fibroblasts (EF) (Abs.). J. Bone Miner. Res. 11(1):S101; 1996.
104. Ishimi, Y.; Miyaura, C.; Jin, C. H.; Akatsu, T.; Abe, E.; Nakamura, Y.; Yamaguchi, A.; Yoshiki, S.; Matsuda, T.; Hirano, T.; Kishimoto, T.; Suda, T. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145:3297-3303; 1990.
105. Green, H.; Schotland, S.; Sella, Z.; Kleeman, C. R. Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells. J. Clin. Invest. 93:2340-2350; 1994.
106. Littlewood, A. J.; Aarden, L. A.; Evans, D. B.; Russell, R. G. G.; Gowen, M. Human osteoblastlike cells do not respond to interleukin-6. J. Bone Miner. Res. 6:141-148; 1991.
107. Feyen, H. J. M.; Elford, P.; Ki Padova, F. E.; Trechsel, U. Interleukin-6 is produced by bone and modulated by parathyroid hormone. J. Bone Miner. Res. 4:633-638; 1989.
108. Greenfield, E. M.; Gornik, S. A.; Horowitz, M. C.; Donahue, H. J.; Shaw, S. M. In vitro PTH increases both mRNA expression and IL-6 secretion from both osteoblast like cells and rat osteoblasts. J. Bone Miner. Res. 8:1163-1171; 1993.
109. Löwik, C. W. G. M.; van der Pluijm, G.; Bloys, H.; Hoekman, K.; Bijvoet, O. L. M.; Asrden, L. A.; Papapoulos, S. E. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Comm. 162:1546-1552; 1989.
110. Rahman, S.; Bunning, R. A. D.; Dobson, P. R. M.; Evans, D. B.; Chapman, K.; Jones, T. H.; Brown, B. L.; Russell, R. G. G. Bradykinin stimulates the production of prostaglandin E2 and interleukin-6 in human osteoblast-like cells. Biochim. Biophys. Acta 1135:97-102; 1992.
111. Zheng, M. H.; Wood, D. J.; Wysocki, S.; Papadimitriou, J. M.; Wang, E. A. Recombinant human bone morphogenetic protein-2 enhances expression of interleukin-6 and transforming growth factor-b1 genes in normal human osteoblast-like cells. J. Cell Physiol. 159:76-82; 1994.
112. Al-Humidan, A.; Ralston, S. H.; Hughes, D. E.; Chapman, K.; Aarden, L.; Russell, R. G. G.; Gowen, M. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J. Bone Miner. Res. 6:3-8; 1991.
113. Flanagan, A. M.; Stow, M. D.; Williams, R. The effect of interleukin-6 and soluble interleukin-6 receptor protein on the bone resorptive activity of human osteoclasts generated in vitro. J. Pathol. 176:289-297; 1995.
114. Kurihara, N.; Bertolini, D.; Suda, T.; Akiyama, Y.; Roodman, G. D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144:4226-4230; 1990.
115. Tamura, T.; Udagawa, N.; Takahashi, N.; Miyaura, C.; Tanaka, S.; Koishihara, Y.; Ohsugi, Y.; Kumaki, K.; Taga, T.; Kishimoto, T.; Suda, T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA 90:11924-11928; 1993.
116. Roodman, G. D.; Kurihara, N.; Ohsaki, Y.; Kukita, T.; Hosking, D.; Demulder, A.; Singer, F. R. Interleukin-6: a potential autocrine/ paracrine factor in Paget's disease of bone. J. Clin. Invest. 89:46-52; 1992.
117. Black, K. S.; Mundy, G. R.; Garrett, I. R. Interleukin-6 causes hypercalcemia in vivo, and enhances the bone resorbing potency of interleukin-1 and tumor necrosis factor by two orders of magnitude in vitro. J. Bone Miner. Res. 6(1):S271; 1991.
118. Girasole, G.; Jilka, R. L.; Passeri, F.; Boswell, S.; Boder, G.; Williams, D. C.; Manologas, S. C. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89:883-891; 1992.
119. Ohsaki, Y.; Takahashi, S.; Scarcez, T.; Demulder, A.; Nishihara, T.; Williams, R.; Roodman, G. D. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 131:2229-2234; 1992.
120. Bellido, T.; Jilka, R. L.; Boyce, B. F.; Girasole, G.; Broxmeyer, H.; Dalrymple, S. A.; Murray, R.; Manolagas, S. C. Regulation of interleukin-6. osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin Invest. 95(6):2886-2895; 1995.
121. Poli, V.; Balena, R.; Fattori, E.; Markatos, A.; Yamamoto, M.; Tanaka, H.; Ciliberto, G.; Rodan, G.; Constantini, A. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO 13:1189-1196; 1994.
122. Wong, G. G.; Clark, S. C. Multiple actions of interleukin-6 within a cytokine network. Immunol. Today 9:137-139; 1988.
123. Bataille, R.; Klein, B. Letter to the editor The bone-resorbing activity of interleukin-6. J. Bone Miner. Res. 6:1143-1144; 1991.
124. Gowen, M. Reply: The bone-resorbing activity of interleukin-6 J. J. Bone Miner. Res. 6:1145-1146; 1991.
125. Roodman, G. D. Perspectives Interleukin-6: An osteotrophic factor? J. Bone Miner. Res. 7:475-478; 1992.
126. Ralston, S. H. Analysis of gene expression in human bone biopsies by polymerase chain reaction: Evidence for enhanced cytokine expression in postmenopausal osteoporosis. J. Bone Min. Res. 9:883-890; 1994.
127. Zhang, J.; Keller, E.; Stebler, B.; Ershler, W. B. Orchiectomy increases bone marrow interleukin-b expression in mice. Calcified Tissue International (In press).